Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.59 |
| ▸ | THPO | P40225 | 1/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL467821 | 1.00 | KDM4E (0.59) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL467823 | 1.00 | KDM4E (0.59) | KDM4EMAPTTHRBALOX15NFKB1 | |
| Hydrochloric Acid SCHEMBL11206313 | 0.98 | KDM4E (0.57) | KDM4EMAPTTHRBALOX15NFKB1 | |
| Trifluoroacetic Acid SCHEMBL9661438 | 0.90 | KDM4E (0.49) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL18668768 | 0.85 | KDM4E (0.46) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL1679687 | 0.83 | KDM4E (0.47) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL205286 | 0.83 | KDM4E (0.47) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL205287 | 0.83 | KDM4E (0.47) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL10977192 | 0.83 | KDM4E (0.54) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL4911424 | 0.82 | KDM4E (0.57) | KDM4EMAPTTHRBALOX15NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1307 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1163262-B1 | PHENYLALANINE DERIVATIVES | US GOV HEALTH & HUMAN SERV (US) | 2011-05-11 | — | — | EP | claimed |
| US-20080139456-A1 | Macrocyclic Sh2 Domain Binding Inhibitors | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2008-06-12 | — | — | US | claimed |
| WO-2008067270-A1 | MACROCYCLIC GRB2 SH2 DOMAIN-BINDING INHIBITORS | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-06-05 | — | — | WO | claimed |
| US-7226991-B1 | inhibiting SH2 domain binding with a phosphoprotein; to inhibit proliferation of tumor cells; for inhibiting the growth of human breast cancer cells | UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2007-06-05 | — | — | US | claimed |
| US-6977241-B2 | SH2 domain binding inhibitors | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2005-12-20 | — | — | US | claimed |
| US-20040048788-A1 | Sh2 domain binding inhibitors | DEPARTMENT OF HEALTH AND HUMAN SERVICES, UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, OF THE | 2004-03-11 | — | — | US | claimed |
| EP-1383792-A2 | SH2 DOMAIN BINDING INHIBITORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2004-01-28 | — | — | EP | claimed |
| WO-2004003005-A2 | SH2 DOMAIN BINDING INHIBITORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2004-01-08 | — | — | WO | claimed |
| WO-2002016407-A2 | SH2 DOMAIN BINDING INHIBITORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2002-02-28 | — | — | WO | claimed |
| EP-1163262-A1 | PHENYLALANINE DERIVATIVES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY of the DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-12-19 | — | — | EP | claimed |
| WO-2000056760-A1 | PHENYLALANINE DERIVATIVES | THE UNITED STATES OF AMERICA, REPRESENTED BY SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2000-09-28 | — | — | WO | claimed |
| US-20260146073-A1 | T CELL RECEPTORS TARGETING MUTATED CDKN2A | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (US) | 2026-05-28 | — | — | US | disclosed |
| EP-4748856-A2 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH SELF-DRIVING CHIMERIC ANTIGEN RECEPTORS | Lentigen Technology, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4743578-A2 | THERAPY FOR ALPHA-1 ANTITRYPSIN DEFICIENCY | Precigen, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-12630802-B2 | Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2026-05-19 | — | — | US | disclosed |
| WO-1997008193-A1 | ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY | NOVARTIS AG (CH) | 1997-03-06 | — | — | WO | disclosed |
| WO-1997007131-A1 | ACYLATED OLIGOPEPTIDES CONTAINING PHOSPHOTYROSINE AS INHIBITORS OF PROTEIN TYROSINE KINASES | NOVARTIS AG (CH) | 1997-02-27 | — | — | WO | disclosed |
| EP-0495963-A4 | IMPROVED HYPOGLYCEMICS | — | 1993-09-01 | — | — | EP | disclosed |
| EP-0495963-A1 | IMPROVED HYPOGLYCEMICS | AMYLIN PHARMACEUTICALS, INC. (US) | 1992-07-29 | — | — | EP | disclosed |
| WO-1992003148-A1 | IMPROVED HYPOGLYCEMICS | AMYLIN CORPORATION (US) | 1992-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630802-B2 | Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood | CD274, PDCD1, CD74 | KDM4E 4449/4885MAPT 1803/4885THRB 904/4885 |
| US-20260146073-A1 | T CELL RECEPTORS TARGETING MUTATED CDKN2A | TP53, CD74, HLA-C | KDM4E 1921/4885MAPT 4121/4885THRB 939/4885 |
| US-20080139456-A1 | Macrocyclic Sh2 Domain Binding Inhibitors | ACP1, PPM1D, LASP1 | KDM4E 1848/4885MAPT 4810/4885THRB 1052/4885 |
| US-20040048788-A1 | Sh2 domain binding inhibitors | ACP1, PHLPP1, SORBS1 | KDM4E 572/4885MAPT 4737/4885THRB 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.